There are 29 papers on MGP in aging research: 1 trial and 10 observational studies in people, 7 in animals, 1 in cells, 7 reviews.
At a glance
The findings reach people, from one lab or study. 3 independent labs in 2 countries.
“Increased MGP (OR = 0.85) and HP (OR = 0.96) decreased the risk of low grip strength”
None of its findings points the other way.
- 3 independent labs in 2 countries
- Funders: National Natural Science Foundation of China and 4 more
- Human trial1
- Humans10
- Animals7
- Cells1
- In silico3
Interventions
1Caloric restriction
no changein rats1
1 study
Caloric restriction
no changein rats1
Caloric restriction showed no clear effect on MGP in rats.
Animalstracheal cartilage
Effects
3Osteosarcopenia
downin silico1
1 study
Osteosarcopenia
downin silico1
MGP protects against osteosarcopenia in silico.
In silico
Trabecular bone volume
upin mice1
1 study
Trabecular bone volume
upin mice1
MGP increases trabecular bone volume in mice (shown by osteoblast-specific knockout).
Animalsshown by osteoblast-specific knockouttrabecular bonemales
Cellular senescence
downin mice1
1 study
Cellular senescence
downin mice1
MGP decreases cellular senescence in mice (shown by osteoblast-specific knockout).
Animalsshown by osteoblast-specific knockoutosteoblasts
Associations
2Frailty-related muscle aging
upin silico1
1 study
Frailty-related muscle aging
upin silico1
MGP is associated with frailty-related muscle aging in silico.
In silico
Muscle weakness
downin humans1OR 0.85
1 study
Muscle weakness
downin humans1OR 0.85
MGP is linked with a lower risk of muscle weakness in humans (OR = 0.85).
Humans